NASDAQ: DCTH - Delcath Systems, Inc.

Yield per half year: +51.2%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Delcath Systems, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma.

more details
The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2018-05-29
ISIN US24661P8077
Industry Health Care Equipment & Supplies
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.delcath.com
Цена ао 4.61
Change price per day: -0.0835% (11.97)
Change price per week: +8.63% (11.01)
Change price per month: +6.6% (11.22)
Change price per 3 month: +30.93% (9.135)
Change price per half year: +51.2% (7.91)
Change price per year: +187.5% (4.16)
Change price per 3 year: +44.44% (8.28)
Change price per 5 year: +29 725.44% (0.0401)
Change price per 10 year: -0% (11.96)
Change price per year to date: +22.79% (9.74)
All parameters

Underestimation

Title Value Grade
P/S 31.52 1
P/BV 4.13 4
P/E 0 0
EV/EBITDA -1.67 0
Total: 3.75

Efficiency

Title Value Grade
ROA, % -123.48 0
ROE, % -302.2 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.2898 10
Total: 8

Growth impulse

Title Value Grade
Yield Revenue, % 29.06 4
Yield Ebitda, % 154.76 10
Yield EPS, % -99.44 0
Total: 5.8
More

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.0467 17.09 1.54048



Head Job title Payment Year of birth
Mr. Gerard J. Michel MBA, MS CEO & Director 727.97k 1963 (62 years)
Dr. Johnny John M.D. Senior Vice President of Clinical Operations & Medical Affairs 472.16k 1965 (60 years)
Ms. Sandra Pennell Senior VP of Finance and Principal Financial & Accounting Officer N/A 1980 (45 years)
Mr. David Hoffman General Counsel, Corporate Secretary & Chief Compliance Officer N/A
Dr. Martha S. Rook Ph.D. Chief Operating Officer N/A 1970 (55 years)
Dr. Vojislav Vukovic M.D., M.Sc., Ph.D. Chief Medical Officer 1967 (58 years)

Address: United States, New York. NY, 1633 Broadway - open in Google maps, open in Yandex maps
Website: https://www.delcath.com